Your browser doesn't support javascript.
loading
Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
Huemer, F; Weiss, L; Regitnig, P; Winder, T; Schmitt, C A; Thaler, J; Wöll, E; Greil, R.
Afiliación
  • Huemer F; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzb
  • Weiss L; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzb
  • Regitnig P; Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Winder T; Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria; Department of Internal Medicine II, Hospital Feldkirch, Feldkirch, Austria.
  • Schmitt CA; Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria; Johannes Kepler University, Kepler University Hospital, Department of Hematology and Oncology, Linz, Austria.
  • Thaler J; Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria; Department of Internal Medicine IV, Hematology and Oncology, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Wöll E; Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria; St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria.
  • Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzb
ESMO Open ; 9(4): 102973, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38507896
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma / Receptor ErbB-2 / Unión Esofagogástrica / Recurrencia Local de Neoplasia Límite: Humans Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma / Receptor ErbB-2 / Unión Esofagogástrica / Recurrencia Local de Neoplasia Límite: Humans Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article